![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
University Hospital, Rouen |
---|---|
Information provided by: | University Hospital, Rouen |
ClinicalTrials.gov Identifier: | NCT00213512 |
to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.
Condition | Intervention | Phase |
---|---|---|
Pemphigus |
Drug: Mabthera |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Health Services Research, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera). |
Estimated Enrollment: | 22 |
Study Start Date: | June 2003 |
Study Completion Date: | October 2008 |
Primary Completion Date: | June 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Rouen University Hospital ( PAIRE Christian / Managing Director ) |
Study ID Numbers: | 2002/020/HP |
Study First Received: | September 13, 2005 |
Last Updated: | February 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00213512 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Autoimmune Diseases Immunologic Factors Skin Diseases, Vesiculobullous Skin Diseases |
Rituximab Antirheumatic Agents Pemphigus |
Autoimmune Diseases Immunologic Factors Immune System Diseases Skin Diseases Skin Diseases, Vesiculobullous Antineoplastic Agents |
Rituximab Therapeutic Uses Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions Pemphigus |